Download Files:
BQ-788 (sodium salt)
$180 – $613
Products Details
Product Description
– BQ-788 sodium salt is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC50 of 1.2 nM in human Girrardi heart cells[1].
Web ID
– HY-15894
Storage Temperature
– -20°C (Powder, protect from light, stored under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C34H50N5NaO7
Citations
– BMC Cancer. 2018 Feb 6;18(1):154.|Environ Sci Pollut Res Int. 2018 May;25(15):14713-14725.|PLoS Pathog. 2020 Oct 19;16(10):e1008947.|Cells. 2021, 10(11), 3072.|Environ Pollut. 2016 Feb;209:11-20.|Environ Pollut. 2016 Nov;218:487-496. |Neurotherapeutics. 2021 Oct 18.|Toxicol Sci. 2016 Jan;149(1):213-26.
References
– [1]Okada M, et al. BQ-788, a selective endothelin ET(B) receptor antagonist. Cardiovasc Drug Rev. 2002 Winter;20(1):53-66.|[2]Sargent CA, et al. Effect of endothelin antagonists with or without BQ 788 on ET-1 responses in pithed rats. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S216-8.|[3]Fattori V, et al. Differential regulation of oxidative stress and cytokine production by endothelin ETA and ETB receptors in superoxide anion-induced inflammation and pain in mice. J Drug Target. 2016 Oct 5:1-27
CAS Number
– 156161-89-6
Molecular Weight
– 663.78
Compound Purity
– 98.56
SMILES
– CCCC[C@H](C(O[Na])=O)NC([C@@H](CC1=CN(C(OC)=O)C2=CC=CC=C12)NC([C@H](CC(C)(C)C)NC(N3[C@H](C)CCC[C@@H]3C)=O)=O)=O
Clinical Information
– Phase 1
Research Area
– Cardiovascular Disease; Endocrinology; Cancer
Solubility
– DMSO : ≥ 43 mg/mL|H2O : 20 mg/mL (ultrasonic)
Target
– Endothelin Receptor
Isoform
– ETB
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
